CHARLOTTE, N.C., March 8, 2006 (PRIMEZONE) -- Chelsea Therapeutics International, Ltd. (OTCBB:CHTP), announced today that President and CEO, Dr. Simon Pedder, will be presenting at the Sachs Associates 5th Annual North American Forum for Investing and Partnering in Biotech at 11:50 A.M. ET on Monday, March 13th at the Fairmont Copley Plaza hotel in Boston. Dr. Pedder's presentation will be webcast live and can be accessed on the investors section of the Chelsea website at www.chelseatherapeutics.com.
About Chelsea Therapeutics
Chelsea Therapeutics is a biopharmaceutical development company that acquires and develops innovative products for the treatment of a variety of human diseases. Chelsea develops technologies that address important unmet medical needs or offer improved, cost-effective alternatives to current methods of treatment. Early clinical data suggests that Chelsea's lead product candidate, CH-1504, may support a safe and effective treatment for rheumatoid arthritis and may have further applications for psoriasis, certain cancers and other immunological disorders.
This press release contains forward-looking statements regarding future events. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include risks and costs of drug development, our history of losses and need to raise more money, regulatory approvals, intellectual property risks, our reliance on our lead drug candidate CH-1504, competition, market acceptance for our products if any are approved for marketing, reliance on key personnel including specifically Dr. Pedder, management of rapid growth, and the need to acquire or develop additional products.